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The objective of this study was to determine differences in airway sensitivity to adenosine 5’-monophosphate
(AMP) between allergic rhinitis subjects with plateau and those without evidence of plateau on the concentration–
response curves to methacholine.
A total of 51 adults (38 subjects with allergic rhinitis and 13 healthy controls) were challenged with increasing
concentrations of methacholine and AMP. The methacholine challenge was terminated when there was a 40% or
more decrease in forced expiratory volume in 1 sec (FEV1), whereas the AMP challenge was stopped when FEV1
had fallen by more than 20%.
A plateau for methacholine was detected in all 13 healthy controls and in 27 patients with allergic rhinitis (AR-
plateau group), whereas 11 subjects with allergic rhinitis did not exhibit a plateau (AR-non-plateau group). The
median (range) PC20 AMP (provocative concentration required to produce a 20% fall in FEV1) value for the AR-
non-plateau group was 44?0mgml71 (3?3–400?0), compared with 400?0mgml71 (12?1–400?0) in the AR-plateau
group (P0?03) and 400?0mgml71 in the healthy control group (P0?007). The proportion of subjects who
showed bronchoconstriction in response to AMP was higher in the AR-non-plateau group (73%) than in the AR-
plateau group (30%) (P0?03). However, three subjects with allergic rhinitis who had normal sensitivity to
methacholine and plateau showed bronchoconstriction in response to AMP.
We conclude that, in subjects with allergic rhinitis, the absence of plateau on the concentration–response curves
to methacholine is associated with a higher prevalence and degree of bronchoconstriction in response to AMP.
However, the two bronchoconstrictor stimuli were not identifying the same abnormalities of the airways.
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It is widely appreciated that asthma is an inflammatory
disease of the airways associated with airway hyper-
responsiveness and variable airflow obstruction (1). Metha-
choline challenge has been widely used for the detection and
quantitation of airway responsiveness (2), and the response
to this bronchoconstrictor agent is commonly expressed as
the provocative concentration (PC20) or dose (PD20)
causing a 20% fall in forced expiratory volume in 1 sec
(FEV1). However, airway hyper-responsiveness can be
defined as the tendency of the airways to narrow too easily
and too much in response to a wide variety of provoking
stimuli (3). Airway narrowing that occurs too easily (airwayReceived 27 September 2000 and accepted in revised form 23
February 2001.
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0954-6111/01/060457+07 $35?00/0sensitivity) is assessed by measuring the interpolated PC20,
but this measure does not assess excessive bronchoconstric-
tion (4,5). Thus, complete description of the dose–response
curve requires at least two parameters, one for sensitivity
(PC20) and one for maximal response (plateau). A plateau
on the concentration–response curve to inhaled methacho-
line is a feature of healthy subjects, whereas it is very
infrequently detected in asthmatics (6,7).
Multiple investigations have shown that increased
sensitivity to methacholine is a common feature in non-
asthmatic subjects with allergic rhinitis (8–10). Further-
more, when exposed to high concentrations of methacho-
line, an appreciable number of subjects with allergic rhinitis
show a maximal response plateau, but plateau is not
detected in a significant proportion (about 35%) of patients
(11,12).
Besides methacholine, an important proportion of
subjects with allergic rhinitis also have increased sensitivity
to inhaled adenosine 5’-monophosphate (AMP) (13,14).
Methacholine-induced bronchoconstriction is likely to be# 2001 HARCOURT PUBLISHERS LTD
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receptors on airway smooth muscle. In contrast, the
underlying mechanism of bronchoconstriction induced by
AMP is mainly indirect, involving mast cell mediator
release (15–17). A recent study (14) showed that although
methacholine and AMP sensitivity are significantly related,
the two bronchoconstrictor agents do not always identify
the same individuals with allergic rhinitis, suggesting that
sensitivity to the two bronchoconstrictor agents is not
reflecting the same abnormalities of the airways.
Polosa et al. (18) have recently demonstrated that, in
subjects with allergic rhinitis, airway sensitivity to AMP is
more strongly related to airway inflammation than is that
to methacholine. Furthermore, we have found that, in non-
asthmatic subjects with allergic rhinitis, the absence of
plateau on the concentration–response curve to methacho-
line is associated with increased numbers of eosinophils in
induced sputum (unpublished data). In asthmatics, airway
inflammation is also related with the level of plateau on the
concentration–response curves to methacholine, but not
with the sensitivity to this bronchoconstrictor agent (19). In
addition, inhaled corticosteroids have been shown to reduce
the maximal response to methacholine with little effect on
the sensitivity (20). Taken together, these observations
confirm the role of inflammatory mechanisms in determin-
ing both the maximal response plateau to methacholine and
the sensitivity to AMP.
In this study we have tested the hypothesis that
bronchoconstriction in response to AMP identifies those
subjects with allergic rhinitis who had no plateau. To that
end, we investigated differences in airway sensitivity to
AMP between allergic rhinitis subjects with plateau and
those without evidence of plateau on the concentration–
response curves to methacholine.
Materials and methods
SUBJECTS
The study population comprised 40 subjects with allergic
rhinitis and 13 healthy controls. Subjects with allergic
rhinitis were recruited consecutively from our outpatient
clinic, whereas healthy subjects were recruited from
volunteers in our institution and among students. All 53
subjects were life-long non-smokers, and none had history
of chronic bronchitis, emphysema or respiratory tract
infections during the 4 weeks before the study. The subjects’
baseline FEV1 was more than 80% predicted. Current or
ex-smokers, pregnant women and patients with significant
renal, hepatic or cardiovascular disease were specifically
excluded.
Subjects with allergic rhinitis were defined as those
individuals with a characteristic history of perennial or
seasonal allergic rhinitis (rhinorrea, sneezing, nasal itch,
nasal obstruction) and who also had skin sensitization to
perennial or seasonal allergens. No subject had a present or
past history of asthma (wheezing, dyspnoea, chest tight-
ness, chronic cough or exercise wheeze).Healthy subjects had no history of asthma, allergic
rhinitis, atopic eczema or other relevant disease, and were
receiving no medication. Three were atopic as defined by a
skin wheal response 43mm to at least one allergen.
The study protocol had been approved by the local ethics
committee, and written informed consent was obtained
from all participants.
STUDY DESIGN
Allergic rhinitis subjects with only seasonal symptoms and
skin sensitization to pollen allergens were studied during a
period of natural pollen exposure (April–June), whereas
those with perennial symptoms were studied during a
period of maximal exposure to mites (October–December).
The study was of an open design. On a screening day
prior to the study, the inclusion and exclusion criteria were
examined and spirometry and skin prick test were
performed. On the second visit (2–30 days after initial
evaluation), complete methacholine concentration–re-
sponse curves were obtained, followed after 7–11 days
(visit 3) by an AMP inhalation test. Each subject attended
the laboratory at the same time of the day during each visit
(+2 h) and baseline FEV1 varied by less than 10%.
SPIROMETRY
Expiratory flows were measured with a calibrated dry
rolling seal spirometer (Model 2130, Sensormedics Co.,
Yorba Linda CA, U.S.A.) according to standardized
guidelines (21). Baseline FEV1 and forced vital capacity
(FVC) were measured until three reproducible recordings
were obtained. Highest values were used for analyses.
Manoeuvres were accepted as technically satisfactory if the
variation of the two best FEV1 values was below 5%, if the
back-extrapolated volume was lower than 100ml or 5%
FEV1 and if the expiratory time was at least 6 sec.
Reference values were those of the European Community
for Coal and Steel (22).
SKIN PRICK TEST
In subjects with allergic rhinitis, atopic status was measured
by skin prick tests using 13 common allergens applied to the
forearm. The allergens (ALK-Abello´, Madrid, Spain) tested
were house dust mites (Dermatophagoides pteronyssinus and
Dermatophagoides farinae), household pets (cat and dog),
pollens (mixed grass, Platanus orientalis, olive, mixed weed
and Parietaria judaica) and moulds (alternaria, Aspergillus
fumigatus, cladosporium and penicillium). Histamine and
glycerinated saline were used as positive and negative
controls. In healthy subjects, skin-prick testing was
performed with the six most common aeroallergens found
in the Valencia area (Dermatophagoides pteronyssinus,
mixed grass, olive, Parietaria judaica, and cat and dog
dander). After 20min wheal size was recorded as the long
axis and its perpendicular. A skin test was considered
positive if the mean wheal diameter was at least 3mm.
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Inhalation provocation tests were performed according to a
2-min tidal breathing method (23) with the nose clipped.
Subjects were instructed to withhold their treatment for at
least 2 weeks (nasal topical corticosteroids and nasal topical
cromoglycate) and 3 days (anti-histamines) prior to each
challenge. The solutions were administered at room
temperature as aerosols generated from a starting volume
of 2ml in Hudson 1720 nebulizers (Temecula, CA, U.S.A.).
The mean+standard deviation (SD) outputs of two
nebulizers were determined by weighing each nebulizer
before and after 2-min nebulizations on six occasions.
These were 0?16+0?03 for the methacholine nebulizer and
0?15+0?02 for the AMP nebulizer.
Methacholine chloride and AMP (Sigma Chemical Co.,
St. Louis, MO, U.S.A.) were dissolved in normal saline to
produce doubling concentrations, range 0?39–200mgml71
for methacholine and 1?56–400mgml71 for AMP, and
immediately used for bronchial challenge. The first
nebulization administered in each challenge was normal
saline, and the post-saline FEV1 was used as the baseline
for the calculation of subsequent percentage fall in FEV1.
After challenge with saline, doubling concentrations of
methacholine chloride or AMP were inhaled. Because of
the effect of a deep inspiration on subsequent airway tone
(24), only one measurement for FEV1 was performed 60–
90 sec after inhalation of each concentration unless the
forced expiratory manoeuvre was judged to be technically
unsatisfactory. The methacholine challenge was stopped
when there was a 40% or more decrease in FEV1 when the
highest concentration had been inhaled, or if unpleasant
side effects or dyspnoea compelled the patient to stop. The
AMP challenge was continued until a concentration of
400mgml71 had been given or until a 20% decrease in
FEV1 was achieved. Two inhalations of salbutamol (200 mg)
from a metered-dose inhaler were then administered to each
subject, and the FEV1 was measured 15min later. Further
doses of salbutamol were given if necessary until the FEV1
returned to 490% of the post-saline value.
DATA ANALYSIS
A concentration–response curve was obtained from each
challenge by plotting the percentage change in FEV1 from
the post-saline value against the logarithm of the concen-
tration of agonist. The methacholine concentration–re-
sponse curves were characterized by their sensitivity (PC20)
and, if possible, by their maximal response plateau level.
Methacholine PC20 was calculated from the log concentra-
tion–response curves by linear interpolation of the two
adjacent data points. A plateau response was considered to
be present if three or more data points for the highest
concentrations of methacholine fell within a 5% response
range. The level of the maximal FEV1 response was
obtained by averaging the data points on the plateau (25).
The AMP concentration–response curves were character-
ized by their PC20.A methacholine PC20 value of 200mgml
71 was assigned
to 11 patients with allergic rhinitis and to eight healthy
subjects in whom FEV1 dropped less than 20% even when
the highest concentration of methacholine was used.
Further, a PC20 value for AMP could not be calculated in
22 subjects with allergic rhinitis and 13 healthy subjects. On
these occasions the PC20 value was censored to the highest
concentration of AMP given (400mgml71).
All summary statistics are expressed as means+SEM
except for PC20 values. To evaluate normality of distribu-
tions the Kolmogorov–Smirnov test was used. Because the
PC20 values were not normally distributed even after
logarithmic transformation, statistical analysis was per-
formed with the non-parametric Kruskal–Wallis test for
differences among the groups. When the results of this test
indicated significant difference, each pairing was examined
by means of the Mann-Whitney U-test. The distributions of
all other variables were not significantly different from a
standard normal distribution; hence, Student’s t-test and
one-way analysis of variance (ANOVA) followed by a post-
hoc t-test for multiple comparisons were applied. Catego-
rical variables were analysed with the Fisher’s exact test.
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS for Windows, release
6?01; SPSS Inc., Chicago, IL, U.S.A.). Statistical signifi-
cance was assumed for P50?05.
Results
BASELINE CHARACTERISTICS
Fifty-one of the 53 subjects completed the study. Two
subjects with allergic rhinitis stopped the methacholine
challenge prematurely because of dyspnoea and cough.
Data of these two patients have not been included in the
analysis because no comment can be made regarding the
presence or absence of a plateau. A maximal response
plateau on the concentration–response curve to methacho-
line was detected in all 13 healthy controls and in 27
patients with allergic rhinitis (AR-plateau group), whereas
11 subjects with allergic rhinitis showed concentration–
response curves without evidence of plateau (AR-non-
plateau group).
The anthropometric, clinical and pulmonary function
data at baseline for the subjects who completed the study
are shown in Table 1. The three groups did not differ with
respect to age, sex and baseline pulmonary function.
Moreover, both groups with allergic rhinitis were similar
with respect to duration of symptoms and prevalence of
skin sensitization to perennial or seasonal allergens. As
expected, the PC20 methacholine values were significantly
lower (P50?001) in the AR-non-plateau group than in
either the AR-plateau group or the healthy control group
(Table 1). Although the PC20 values were lower in the AR-
plateau group than in the healthy control group, this
difference was not significant (P0?14). Mean baseline
FEV1 values were not significantly different within the three
groups before the two different provocation tests.
TABLE 1. Demographics and functional characteristics
Allergic rhinitis
Non-plateau group Plateau group Healthy
Number 11 27 13
Age (yrs) 28?3+2?9 31?7+1?8 36?0+3?5
Male/female 5/6 17/10 5/8
Duration of symptoms (yrs) 7?1+2?0 8?6+1?5 —
Perennial/seasonal 5/6 13/14 —
FEV1 (% predicted) 105?2+3?8 108?1+1?8 111?8+2?5
FEV1/FVC % 84?2+1?5 85?4+1?1 86?6+1?0
PC20 methacholine (mgml
–1)* 2?5 (0?6–7?1) 70?3 (1?2–200?0) 200?0 (11?6–200?0)
Prechallenge FEV1 (l)
Methacholine 3?71+0?24 4?04+0?17 3?84+0?25
AMP 3?74+0?21 4?05+0?18 3?79+0?23
FEV1: forced expiratory volume in 1 sec; FVC: forced vital capacity; PC20: provocative concentration of agonist required to
produce a 20% fall in FEV1.
Values are means+SEM.
*Data presented as median with range in parentheses.
FIG. 1. PC20 AMP values in the three groups. Horizontal
lines indicate the medians; shaded areacensored values.
AR-plateauallergic rhinitis subjects with a plateau; AR-
non-plateausubjects with allergic rhinitis without
evidence of plateau.
FIG. 2. Individual values for level of plateau in allergic
rhinitis subjects with a plateau who showed
bronchoconstriction in response to AMP and in those
without bronchoconstriction in response to AMP.
Horizontal lines are means.
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GROUPS
The median (range) PC20 AMP value for the AR-non-
plateau group (Fig. 1) was 44?0mgml71 (3?3–400?0),
compared with 400?0mgml71 (12?17400?0) in the AR-
plateau group (P0?03) and 400?0mgml71 in the healthy
control group (P0?007). No significant differences weredetected between the AR-plateau group and the healthy
control group (P0?13).
The proportion of subjects who showed bronchoconstric-
tion in response to AMP was higher in the AR-non-plateau
group (eight out of 11) than in the AR-plateau group (eight
out of 27) (P0?03). Both groups with allergic rhinitis had a
greater prevalence of bronchoconstriction in response to
AMP than healthy controls (P50?05). Furthermore, in the
AR-plateau group, the level of plateau (Fig. 2) was
significantly higher in subjects who showed bronchocon-
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this bronchoconstrictor agent (31?0+1?5% vs. 17?5+1?3%,
P50?001).
When we analysed the individual responses to both
bronchoconstrictor agents, it was evident that AMP and
methacholine hyper-responsiveness was not always detected
in the same individuals with allergic rhinitis. Three subjects
of the AR-non-plateau group failed to respond to AMP. In
addition, bronchoconstriction in response to AMP was
detected in three subjects with allergic rhinitis who had
normal sensitivity to methacholine (PC2048mgml
71) and
a plateau.
Discussion
The results of the present study indicate that non-asthmatic
subjects with allergic rhinitis without evidence of plateau on
the concentration–response curves to methacholine have a
higher prevalence and degree of bronchoconstriction in
response to inhaled APM than allergic rhinitis subjects with
plateau. Furthermore, the results also show that the
presence of airway hyper-responsiveness to methacholine
(increased sensitivity and absence of plateau) is not
necessarily accompanied by bronchoconstriction in re-
sponse to AMP, and that inhaled AMP causes airway
narrowing in a significant proportion of allergic rhinitis
subjects without airway hyper-responsiveness to methacho-
line. These findings confirm that the two bronchoconstric-
tor agents are not identifying the same abnormalities of the
airways in subjects with allergic rhinitis.
Our study shows that bronchoconstriction in response to
inhaled AMP is detected in 42% of subjects with allergic
rhinitis, and this is in keeping with our previous observa-
tions (14). By contrast, Phillips et al. (13) measured airway
responsiveness to AMP in 10 atopic non-asthmatic subjects.
In this study seven subjects (70%) had a PC20 value
400mgml71. There are several possible explanations for
this apparent discrepancy. In the study by Phillips et al.
(13), the nebulizer output was 0?48mlmin71 and subjects
inhaled the aerosolized solutions in five consecutive breaths
from end tidal volume to full inspiratory capacity. In
contrast, the nebulizer used in the present study had an
output of 0?15mlmin71 and subjects inhaled the aerosol by
tidal breathing for 2min. Furthermore, it is important to
emphasize that subjects in the study by Phillips et al. (13)
were not selected on the presence of allergic rhinitis, but on
the basis of the presence of atopy.
At present, airway responsiveness is usually measured in
concentration–response curves as the provocative concen-
tration of histamine or methacholine causing a fall of 20%
in FEV1, which is called the sensitivity (PC20). Thus, the
terms airway hyper-responsiveness and hypersensitivity are
used interchangeably. However, some studies (5) have
focused on the importance of characterizing the entire
methacholine concentration–response curve not only by
sensitivity, but also by the maximal airway narrowing
response value (plateau). In our study, methacholine
responsiveness was characterized by the sensitivity and
the magnitude of airway narrowing. A maximal responseplateau on the concentration–response curves was detected
in 27 (71%) of our patients with allergic rhinitis and this is
in keeping with previous reports (9,11,12). However, our
subjects with allergic rhinitis were tested during a period of
maximal natural allergenic exposure and previous studies
have demonstrated that natural allergenic exposure causes
the loss of plateau in a significant number of subjects with
asthma (26) or allergic rhinitis (27). This may explain the
high prevalence of allergic rhinitics without evidence of
plateau in this study. In addition, airway sensitivity to
inhaled AMP increases during periods of natural allergen
exposure in asthmatics (28), but the effect of allergen
exposure on AMP sensitivity has not been evaluated in
subjects with allergic rhinitis.
Although the association between airway inflammation
and bronchial hyper-responsiveness in asthma is a widely
accepted concept (29), the pathogenesis of bronchial hyper-
responsiveness associated with allergic rhinitis is still
debated. However, inflammatory changes such as eosino-
phil accumulation (18,30–32) and enhanced collagen
deposition in the lower airways (33) are seen in both
allergic rhinitis and asthma, although it occurs to a lesser
degree in patient with allergic rhinitis who have no
symptoms of asthma. One of our reasons for undertaking
this study was the hypothesis that if both the maximal
response plateau to methacholine and sensitivity to AMP
depend, at least in part, on the presence of inflammatory
cells in the lower airways (18,19), bronchoconstriction in
response to AMP might be detected in subjects with allergic
rhinitis who had no plateau. In the current study, the
proportion of subjects who showed bronchoconstriction in
response to AMP was significantly higher in allergic rhinitis
subjects without plateau than in those with plateau, and
subjects with allergic rhinitis who had no plateau were more
sensitive to AMP than those who achieved a plateau.
Therefore, lack of a plateau was an indication of greater
sensitivity to AMP. However, an important proportion of
subjects did not conform to this relationship. Eight of our
27 (30%) rhinitics with plateau had bronchoconstriction in
response to AMP. In addition, there were subjects (27%)
who were insensitive to AMP who had no plateau despite
decreases in FEV1440%. Thus, our hypothesis that
bronchoconstriction in response to AMP identifies those
subjects with allergic rhinitis who had no plateau was not
confirmed. On the contrary, our results support the
proposal that, at least in patients with allergic rhinitis,
methacholine and AMP responsiveness are not reflecting
the same abnormalities of the airways.
We do not believe that our findings can be explained by
measurement errors, since the results were obtained after
carefully addressing such aspects of methodology as study
design and challenge methods. Firstly, there were no
significant differences between the baseline airway calibre
prior to bronchial challenge on any of the study days. Thus,
effects caused by differing baseline airway calibre on the
subsequent determination of PC20 could be eliminated. In
addition, challenges were carried out at the same time of the
day, thus ruling out a possible influence of circadian
variations on airway responsiveness. Secondly, inhalation
challenges were not performed randomly and there is a
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have influenced the AMP test. However, this seems to be
unlikely, since the study days were separated by 7–11 days.
Thirdly, none of the subjects was being treated with
medications that could have affected the response to
bronchoconstrictor agents. Moreover, by subjecting each
volunteer to all provocations, it was possible to make a
direct comparison of the effects of each agonist in the same
subjects.
In our study, estimation of the airway sensitivity to both
bronchoconstrictor agents was complicated because 11
(41%) allergic rhinitis patients with plateau and eight
(61%) healthy subjects had PC20 methacholine values
above the upper limit of measurement. In addition, 19
(70%) allergic rhinitis subjects with plateau, three (27%)
allergic rhinitis patients without plateau and 13 (100%)
healthy controls had PC20 AMP values above the upper
limit of measurement. A PC20 value of 200mgml
71 for
methacholine and 400mgml71 for AMP was assigned to
these subjects, but this gives an under-estimation of their
true PC20 value. Given these restrictions, the significance of
the differences in the sensitivity of the various groups is
almost certainly an under-estimation.
Another reason for careful interpretation of the study
results is that a proportion of subjects who showed FEV1
falls440% without evidence of plateau might have plateau
beyond a 40% fall from baseline FEV1. The degree of
airway narrowing induced in this study was similar to that
in other reports (9,34), but it is possible that a greater
prevalence of plateaus would have been seen had we
allowed FEV1 to decrease by 440%. In addition, AMP
responsiveness was characterized only by the sensitivity,
and therefore no comment can be made regarding the
relationship between the shape of the concentration–
response curve to both bronchoconstrictor agents. This
should be addressed in future studies.
The present results have clinical implications. It can be
assumed that airway hyper-responsiveness in subjects with
allergic rhinitis represents a latent phase of asthma that
becomes clinically active over the course of time. The
presence of airway hypersensitivity to methacholine in
ragweed-allergic rhinitis has been shown to carry a
substantially increased risk of the development of asthma
over subsequent years (8). However, this study could not be
confirmed by data from a 4-year follow-up in 66 patients
with perennial or seasonal allergic rhinitis (35). Our results
indicate that methacholine and AMP responsiveness are
not identifying the same individuals with allergic rhinitis,
and it is tempting to speculate that in subjects with allergic
rhinitis, the presence of bronchoconstriction in response to
AMP might be an indication of increased susceptibility to
the development of asthma. Further prospective studies are
needed to clarify the prognostic value of AMP responsive-
ness in subjects with allergic rhinitis.
In summary, although subjects with allergic rhinitis who
did not exhibit a plateau in their methacholine response are
more sensitive to inhaled AMP than those who attain a
plateau, inhaled AMP causes airway narrowing in a
significant proportion of subjects with allergic rhinitis and
normal responsiveness to methacholine. These findingssuggest that the two bronchoconstrictor agents are not
identifying the same abnormalities of the airways.
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